Company guidance, FDA catalysts, dilution risk and cash runway, built from SEC, FDA and ClinicalTrials.gov filings and updated every day.
$5MCash on Hand
1.3mo Cash Runway
Follow MDCX by emailGet an email when MDCX reports key news in an SEC filing, pushes back a promised milestone, files for a stock offering, lands on the Downside Radar or has an FDA decision. Free, no account needed.
We send one confirmation email first. Only emails about MDCX, unsubscribe in one click. Privacy
📄 Latest SEC Filings in Plain English
Nov 16, 2026 ·
Financing Exchanged $10.5 million of the A-1 note for 105,000 non-voting preferred shares at $100 each, with no cash received. Separately sold 97,973 common shares and pre-funded warrants for 1,646,213 shares, for about $3.0 million gross at $1.72. Form 424B3 · SEC filing
Nov 16, 2026 ·
Financing Medicus exchanged $10.5 million of its Secured Promissory Note A-1 for 105,000 non-convertible preferred shares at $100 each, with no cash received. It also closed a $3.0 million registered direct offering of 97,973 shares at $1.72 plus pre-funded warrants. Form 8-K · SEC filing
Nov 16, 2026 ·
Financing Medicus Pharma is selling 97,973 common shares and pre-funded warrants for 1,646,213 shares directly to investors, for about $3.0 million gross, at $1.72 per share. A concurrent $1.25 million private placement, including Executive Chairman and CEO Dr. Raza Bokhari, is a condition of the offering. Form 424B5 · SEC filing
Nov 6, 2026 ·
Quarterly report for the period ended Sep 30, 2026 Form 10-Q · SEC filing
Nov 4, 2026 ·
Deal Medicus Pharma announced a non-binding letter of intent for a business combination of its subsidiary SkinJect with an undisclosed SPAC, at a $135 million pre-money enterprise valuation, with concurrent equity financing to support the SKNJCT-005 study in Gorlin syndrome. Form 8-K · SEC filing · Press release
Oct 30, 2026 ·
Shareholder vote Medicus Pharma will hold a special shareholder meeting on December 2, 2026. Shareholders vote on creating Class A blank cheque preferred shares, a share split of up to one pre-split share for every fifty post-split shares at the Board's discretion, and an adjournment proposal. Form DEF 14A · SEC filing
Oct 26, 2026 ·
Listing Nasdaq notified Medicus Pharma that it regained compliance with the $1.00 minimum bid price rule after the shares closed at or above $1.00 for ten consecutive business days, from October 12 to October 23, 2026, which supersedes an earlier October 20 delisting determination letter. Form 424B3 · SEC filing
Oct 23, 2026 ·
Listing Nasdaq notified Medicus Pharma that it regained compliance with the $1.00 minimum bid price rule, closing the matter and superseding an October 20, 2026 delisting determination letter. Shares closed at or above $1.00 for ten consecutive business days, October 12 to October 23, 2026. Form 8-K · SEC filing
Each summary is written by AI from the filing itself, and one that names a number or a name the filing does not contain is not shown. Quarterly and annual reports are listed by period. Read the filing before acting on it.
🧪 Trial & FDA Catalysts
Aug 2014 · Phase 2 · Results Expected · MSM Product on Attenuating Nasal Provocation With a Standardized Allergenic Challenge Registry primary completion date, not a results date
Aug 2014 · Phase 2 · Results Expected · The Effects of the Onion-Pumpkin Extract on Blood Pressure Registry primary completion date, not a results date
Jun 2014 · Phase 1 · Results Expected · DEC033 Study Product for Mild to Moderate Eczema An Open-label, Adaptive-design Pilot Study Registry primary completion date, not a results date
💰 Cash Runway & Dilution Risk
MDCX holds $5M in cash and short-term investments (as of Sep 30, 2026) and burns about $11.5M/quarter from operations,
an estimated runway of 1.3 months at that rate (BioRadar estimate, not company guidance).
Dilution pressure:55 · Elevated
Cash runway 1 months +40
ATM program on file since Jan 2026 +15
Shelf registration (S-3, Dec 2025) +10
Raised after last reported balance sheet (Nov 2026) -10
Share count 1,922,837 (latest 10-Q/10-K). Insiders: each officer's, director's and 10% owner's latest Form 3, 4 or 5, direct and indirect shares; options are not counted. 5%+ holders: latest Schedule 13D or 13G of each holder above 5%. Institutions: the total held by all 13F filers (Yahoo Finance); the table lists the largest. Sources have different dates, so the split is approximate. Source: SEC EDGAR.
Get the full MDCX picture
The 7-day free trial adds AI daily briefings, sentiment tracking, trial enrollment progress and email alerts for MDCX and every other ticker you follow. Card required, cancel anytime.
Data: SEC EDGAR, FDA, ClinicalTrials.gov, Yahoo Finance • Informational purposes only, not investment advice. • All tracked stocks A–Z
This data is for informational purposes only, not investment advice. BioRadar does not provide buy/sell recommendations. Past performance does not guarantee future results. Always do your own due diligence.